Mucositis News and Research

RSS

Daewoong, Medivir sign distribution agreement for Xerclear in China and Hong Kong

Medivir AB, a research-based specialty pharmaceutical company focused on infectious diseases, today announced that it has signed an agreement with Daewoong Pharmaceutical Co. Ltd. to exclusively distribute Medivir's unique cold sore treatment Xerclear in China and Hong Kong.

23 Jun 2011

RHEI receives Chinese SFDA acceptance letter for MuGard

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that its MuGard partner in China, RHEI Pharmaceuticals has received the acceptance letter from the State Food and Drug Administration (SFDA) of China acknowledging all necessary documentation for the MuGard has been submitted and accepted.

17 Jun 2011

Allos Therapeutics reports results from FOLOTYN pivotal trial against peripheral T-cell lymphoma

Allos Therapeutics, Inc. today reported results from a retrospective analysis of data from the Company's pivotal PROPEL trial which suggested that treatment with single-agent FOLOTYN may result in increased response rates and progression-free survival relative to the immediate prior line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.

17 Jun 2011

ABRAXANE and bevacizumab clinical studies on unresectable melanoma presented at ASCO 2011

Celgene International Sàrl today announced that results from two investigator initiated studies including ABRAXANE, and bevacizumab in unresectable melanoma were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL.

7 Jun 2011

Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breast cancer

Celgene International Sàrl today announced that results from an investigator-initiated phase II study of ABRAXANE, gemcitabine and bevacizumab as first-line treatment in metastatic breast cancer were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL.

7 Jun 2011

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

AVEO Pharmaceuticals, Inc., today announced data from the final analysis of its Phase 2 randomized discontinuation trial evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with advanced renal cell carcinoma.

2 Jun 2011

YM announces updates on nimotuzumab clinical development program

YM BioSciences Inc., today provided an update on the development program for nimotuzumab, including its North American clinical program for nimotuzumab, manufacturing scale-up activities, and data presentations anticipated for nimotuzumab at the 2011 Annual Meeting of the American Society of Clinical Oncology.

31 May 2011

PolyMedix presents new pre-clinical data on antimicrobial compounds at two scientific meetings

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, announced today that new pre-clinical data for its novel, defensin-mimetic antimicrobial compounds was recently presented at two prestigious scientific meetings, including the American Society of Microbiology.

25 May 2011

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Exelixis, Inc. today announced the results of the phase 1 clinical trial of cabozantinib in patients with advanced solid tumors or lymphoma have been published in the current issue of the Journal of Clinical Oncology.

24 May 2011

FDA approves SUTENT for treatment of pancreatic NET

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SUTENT® (sunitinib malate) as the first anti-VEGF therapy to treat progressive, well-differentiated pancreatic neuroendocrine tumors (NET) in patients with unresectable locally advanced or metastatic disease. Pancreatic NET is a rare cancer reported in two to four people per million annually worldwide.

21 May 2011

PolyMedix's PMX-30063 compound mitigates ulcerative mucositis in pre-clinical studies

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat patients with acute infectious diseases and cardiovascular disorders, announced today that its lead defensin-mimetic antibiotic compound, PMX-30063, when administered topically as an oral rinse, has shown activity against oral mucositis in an animal study.

19 May 2011

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

Pfizer Inc. today announced data from the pivotal Phase 3 AXIS 1032 trial, showing that in patients with previously treated advanced renal cell carcinoma, axitinib significantly extended progression-free survival at the 47th Annual American Society of Clinical Oncology meeting in Chicago from June 3-7, 2011.

19 May 2011

BioAlliance Pharma enters license deal with Sosei to commercialize Loramyc in Japan

BioAlliance Pharma, a company dedicated to specialty and orphan pharma products in oncology and supportive care, today announced that it has entered into an exclusive licensing agreement with Sosei Co. Ltd. for commercialization rights in Japan for Loramyc muco-adhesive buccal tablet.

11 May 2011

Sosei acquires rights to Loramyc in Japan from BioAlliance Pharma

Sosei Group Corporation, the biopharmaceutical company, today announces that Sosei Co., Ltd., its wholly owned Japanese subsidiary, acquired development and commercialization rights to Loramyc (miconazole Lauriad) in Japan from BioAlliance Pharma.

11 May 2011

Allos, Mundipharma enter strategic collaboration to co-develop FOLOTYN

Allos Therapeutics, Inc. and Mundipharma International Corporation Limited today jointly announced that the companies have entered into a strategic collaboration agreement to co-develop FOLOTYN (pralatrexate injection).

11 May 2011

Major pharmaceutical company, Access sign deal for RNAi therapeutics

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into an agreement with a major pharmaceutical company to exploit its CobaCyte and CobOral technology for the targeted delivery of RNAi therapeutics.

15 Apr 2011

Pfizer to support immatics' IMA901 Phase III trial in advanced renal cell carcinoma

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that Pfizer has agreed to support its pivotal Phase III trial with IMA901, its therapeutic cancer vaccine for advanced renal cell carcinoma.

11 Apr 2011

NephRx receives new U.S. patent for NX002 to treat IBD

NephRx Corporation today announced issuance of a new U.S. patent for use of its novel growth factor peptide NX002 as a potential treatment for inflammatory bowel disease.

24 Mar 2011

NephRx receives new U.S. patent for NX002 to treat oral mucositis

NephRx Corporation today announced issuance of a new U.S. patent for its novel peptide NX002, which currently is in preclinical development for the treatment of oral mucositis.

23 Mar 2011

NIH awards Avaxia Phase I SBIR grant to develop novel antibody therapeutic for celiac disease

Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH), to support the development of a novel antibody therapeutic for celiac disease.

11 Mar 2011

Mucositis News and Research

Daewoong, Medivir sign distribution agreement for Xerclear in China and Hong Kong

RHEI receives Chinese SFDA acceptance letter for MuGard

Allos Therapeutics reports results from FOLOTYN pivotal trial against peripheral T-cell lymphoma

ABRAXANE and bevacizumab clinical studies on unresectable melanoma presented at ASCO 2011

Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breast cancer

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

YM announces updates on nimotuzumab clinical development program

PolyMedix presents new pre-clinical data on antimicrobial compounds at two scientific meetings

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

FDA approves SUTENT for treatment of pancreatic NET

PolyMedix's PMX-30063 compound mitigates ulcerative mucositis in pre-clinical studies

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

BioAlliance Pharma enters license deal with Sosei to commercialize Loramyc in Japan

Sosei acquires rights to Loramyc in Japan from BioAlliance Pharma

Allos, Mundipharma enter strategic collaboration to co-develop FOLOTYN

Major pharmaceutical company, Access sign deal for RNAi therapeutics

Pfizer to support immatics' IMA901 Phase III trial in advanced renal cell carcinoma

NephRx receives new U.S. patent for NX002 to treat IBD

NephRx receives new U.S. patent for NX002 to treat oral mucositis

NIH awards Avaxia Phase I SBIR grant to develop novel antibody therapeutic for celiac disease

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News